{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:31:22Z","timestamp":1793341882006,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.canlet.2026.218902","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:19:17Z","timestamp":1792563557000},"page":"218902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting CDC7 overcomes gemcitabine resistance in cholangiocarcinoma by inducing cellular senescence"],"prefix":"10.1016","volume":"663","author":[{"given":"Rong","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Han","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiuPing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-145X","authenticated-orcid":false,"given":"Jianfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4605-4624","authenticated-orcid":false,"given":"Jing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218902_bib1","article-title":"IDH mutation subgroup status associates with intratumor heterogeneity and the tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"8","author":"Xiang","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218902_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2026.218902_bib3","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218902_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2026.218902_bib5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MOG.0b013e3282fbf9b3","article-title":"Cholangiocarcinoma: lessons from Thailand","volume":"24","author":"Sripa","year":"2008","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.canlet.2026.218902_bib6","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.bjc.6603127","article-title":"Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001","volume":"94","author":"West","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218902_bib7","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2468-1253(21)00171-0","article-title":"Current and emerging therapies for advanced biliary tract cancers","volume":"6","author":"Kam","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2026.218902_bib8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218902_bib9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2026.218902_bib10","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218902_bib11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218902_bib12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218902_bib13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New Horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218902_bib14","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/2159-8290.CD-23-0282","article-title":"An inflammatory checkpoint generated by IL1RN splicing offers therapeutic opportunity for KRAS-mutant intrahepatic cholangiocarcinoma","volume":"13","author":"Zhang","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218902_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218902_bib16","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2026.218902_bib17","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/2159-8290.CD-21-1168","article-title":"EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218902_bib18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2020.05.040","article-title":"A genetic map of the response to DNA damage in human cells","volume":"182","author":"Olivieri","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218902_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239034","article-title":"Checkpoint kinase 1 pharmacological inhibition synergizes with DNA-damaging agents and overcomes platinum resistance in basal-like breast cancer","volume":"21","author":"Nieto-Jimenez","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218902_bib20","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1093\/emboj\/18.20.5703","article-title":"Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication","volume":"18","author":"Jiang","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2026.218902_bib21","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1073\/pnas.0604990103","article-title":"CDC7 kinase phosphorylates serine residues adjacent to acidic amino acids in the minichromosome maintenance 2 protein","volume":"103","author":"Cho","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218902_bib22","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1042\/BST20130217","article-title":"Regulation of chromosome dynamics by Hsk1\/Cdc7 kinase","volume":"41","author":"Matsumoto","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.canlet.2026.218902_bib23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1097-2765(02)00799-2","article-title":"An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication","volume":"11","author":"Costanzo","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218902_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-019-1607-3","article-title":"Inducing and exploiting vulnerabilities for the treatment of liver cancer","volume":"574","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218902_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-023-01315-2","article-title":"Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR\/Cas9 screening","volume":"9","author":"Deng","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.canlet.2026.218902_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf0197","article-title":"A CDC7 inhibitor sensitizes DNA-Damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery","volume":"7","author":"Iwai","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218902_bib27","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.ccell.2025.05.015","article-title":"Senescence in cancer","volume":"43","author":"Colucci","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218902_bib28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","article-title":"Senescence and cancer - role and therapeutic opportunities","volume":"19","author":"Schmitt","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218902_bib29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218902_bib30","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41580-024-00738-8","article-title":"SenNet recommendations for detecting senescent cells in different tissues","volume":"25","author":"Suryadevara","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218902_bib31","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1101\/gad.343129.120","article-title":"Senescence and the SASP: many therapeutic avenues","volume":"34","author":"Birch","year":"2020","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2026.218902_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/35041687","article-title":"Oxidants, oxidative stress and the biology of ageing","volume":"408","author":"Finkel","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218902_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1042\/BJ20130282","article-title":"ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors","volume":"454","author":"Halasi","year":"2013","journal-title":"Biochem. J."},{"key":"10.1016\/j.canlet.2026.218902_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102344","article-title":"TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS\/AMPK\/mTOR\/autophagy signaling","volume":"53","author":"Liu","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.canlet.2026.218902_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2024.101475","article-title":"ZBP1 promotes hepatocyte pyroptosis in acute liver injury by regulating the PGAM5\/ROS pathway","volume":"29","author":"Yan","year":"2024","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.canlet.2026.218902_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2025.103014","article-title":"Crosstalk between calcium and reactive oxygen species signaling in cancer revisited","volume":"127","author":"Pathak","year":"2025","journal-title":"Cell Calcium"},{"key":"10.1016\/j.canlet.2026.218902_bib37","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1038\/s41467-021-25904-w","article-title":"A replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer","volume":"12","author":"Konstantinopoulos","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218902_bib38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13073-021-00981-0","article-title":"Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer","volume":"13","author":"Guo","year":"2021","journal-title":"Genome Med."},{"key":"10.1016\/j.canlet.2026.218902_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103323","article-title":"Tryptanthrin targets GSTP1 to induce senescence and increases the susceptibility to apoptosis by senolytics in liver cancer cells","volume":"76","author":"Zhang","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.canlet.2026.218902_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.redox.2018.04.007","article-title":"Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging","volume":"17","author":"Robinson","year":"2018","journal-title":"Redox Biol."},{"key":"10.1016\/j.canlet.2026.218902_bib41","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1158\/1078-0432.CCR-10-0185","article-title":"Targeting cell division cycle 7 kinase: a new approach for cancer therapy","volume":"16","author":"Montagnoli","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218902_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13046-024-03078-9","article-title":"The novel SMYD3 inhibitor EM127 impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistance","volume":"43","author":"Sanese","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218902_bib43","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202256230","article-title":"FBL promotes cancer cell resistance to DNA damage and BRCA1 transcription via YBX1","volume":"24","author":"Sun","year":"2023","journal-title":"EMBO Rep."},{"key":"10.1016\/j.canlet.2026.218902_bib44","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.celrep.2019.01.005","article-title":"Decreased KAT5 expression impairs DNA repair and induces altered DNA methylation in kidney podocytes","volume":"26","author":"Hishikawa","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218902_bib45","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1038\/onc.2015.321","article-title":"hPso4\/hPrp19: a critical component of DNA repair and DNA damage checkpoint complexes","volume":"35","author":"Mahajan","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218902_bib46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41388-025-03655-y","article-title":"RBM8A confers oxaliplatin resistance in gastric cancer by maintaining EGFR mRNA stability","volume":"45","author":"Ma","year":"2026","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218902_bib47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/1078-0432.CCR-18-0284","article-title":"Combined CDK4\/6 and Pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218902_bib48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.32102","article-title":"Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4\/6 inhibitors in biliary tract cancers","volume":"75","author":"Arora","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218902_bib49","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/hep.30704","article-title":"Dependency of cholangiocarcinoma on cyclin D-Dependent kinase activity","volume":"70","author":"Sittithumcharee","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218902_bib50","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3892\/ol.2025.14874","article-title":"DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines","volume":"29","author":"Lerksuthirat","year":"2025","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2026.218902_bib51","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41417-026-01005-y","article-title":"Ataxia-telangiectasia mutated kinase inhibition overcomes gemcitabine resistance in intrahepatic cholangiocarcinoma via DNA ligase I-dependent repair vulnerability","volume":"33","author":"Lin","year":"2026","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2026.218902_bib52","article-title":"Inhibition of the PLK1-Coupled cell cycle machinery overcomes resistance to oxaliplatin in colorectal cancer","volume":"8","author":"Yu","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218902_bib53","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1158\/1078-0432.CCR-08-1276","article-title":"Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma","volume":"15","author":"Kulkarni","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218902_bib54","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/2767-9764.CRC-22-0277","article-title":"Safety, tolerability, and pharmacokinetics of TAK-931, a cell division cycle 7 inhibitor, in patients with advanced solid tumors: a phase I first-in-human study","volume":"2","author":"Kuboki","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.canlet.2026.218902_bib55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10637-022-01318-3","article-title":"A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors","volume":"41","author":"Steeghs","year":"2023","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.canlet.2026.218902_bib56","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.tcb.2018.04.006","article-title":"Two-step senescence-focused cancer therapies","volume":"28","author":"Sieben","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2026.218902_bib57","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0092-8674(02)00734-1","article-title":"A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy","volume":"109","author":"Schmitt","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218902_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108096","article-title":"ATR restrains DNA synthesis and mitotic catastrophe in response to CDC7 inhibition","volume":"32","author":"Rainey","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218902_bib59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1535-7163.MCT-08-0662","article-title":"Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells","volume":"8","author":"Parsels","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218902_bib60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.20517\/2394-4722.2017.03","article-title":"DNA damage-induced nuclear factor-kappa B activation and its roles in cancer progression","volume":"3","author":"Wang","year":"2017","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.canlet.2026.218902_bib61","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.bcp.2006.04.011","article-title":"NF-kappaB activation by reactive oxygen species: fifteen years later","volume":"72","author":"Gloire","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218902_bib62","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nature03841","article-title":"Oncogene-induced senescence as an initial barrier in lymphoma development","volume":"436","author":"Braig","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218902_bib63","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nature03918","article-title":"Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis","volume":"436","author":"Chen","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218902_bib64","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrc3057","article-title":"Pro-senescence therapy for cancer treatment","volume":"11","author":"Nardella","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218902_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15584","article-title":"Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration","volume":"8","author":"Jayatilaka","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218902_bib66","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1172\/JCI64098","article-title":"Cellular senescence and the senescent secretory phenotype: therapeutic opportunities","volume":"123","author":"Tchkonia","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218902_bib67","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ccell.2020.10.012","article-title":"Senescence reprogramming by TIMP1 deficiency promotes prostate cancer metastasis","volume":"39","author":"Guccini","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218902_bib68","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1242\/jcs.01635","article-title":"Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation","volume":"118","author":"Parrinello","year":"2005","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2026.218902_bib69","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.cellsig.2011.08.001","article-title":"MMP-9 silencing regulates hTERT expression via beta1 integrin-mediated FAK signaling and induces senescence in glioma xenograft cells","volume":"23","author":"Ponnala","year":"2011","journal-title":"Cell. Signal."},{"key":"10.1016\/j.canlet.2026.218902_bib70","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/nature08285","article-title":"Immortalization eliminates a roadblock during cellular reprogramming into iPS cells","volume":"460","author":"Utikal","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218902_bib71","doi-asserted-by":"crossref","first-page":"E5024","DOI":"10.1073\/pnas.1602379113","article-title":"Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence","volume":"113","author":"Patel","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218902_bib72","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature25167","article-title":"Senescence-associated reprogramming promotes cancer stemness","volume":"553","author":"Milanovic","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218902_bib73","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/s41467-017-01992-5","article-title":"Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma","volume":"8","author":"Gonzalez-Meljem","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218902_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115057","article-title":"Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer","volume":"162","author":"Xiong","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2026.218902_bib75","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ccell.2023.04.003","article-title":"Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators","volume":"41","author":"Obradovic","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218902_bib76","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/2159-8290.CD-22-0523","article-title":"Cellular senescence is immunogenic and promotes antitumor immunity","volume":"13","author":"Marin","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218902_bib77","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218902_bib78","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1007\/s11033-010-9975-7","article-title":"Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939\/ADM","volume":"38","author":"Liu","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.canlet.2026.218902_bib79","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159628","article-title":"RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer","volume":"132","author":"Deng","year":"2022","journal-title":"J. Clin. Investig."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600666X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600666X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:44:58Z","timestamp":1793339098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352600666X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":79,"alternative-id":["S030438352600666X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218902","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting CDC7 overcomes gemcitabine resistance in cholangiocarcinoma by inducing cellular senescence","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218902","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218902"}}